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Mannose-binding lectin (MBL), a soluble factor of the innate immune system, is a pattern recognition molecule with a number of
knownligands,includingviruses,bacteria, andmolecules fromabnormalselftissues.Inadditiontoitsroleinimmunity,MBLalso
functions in the maintenance of tissue homeostasis. We present evidence here that MBL binds to amyloid β peptides. MBL binding
to other known carbohydrate ligands is calcium-dependent and has been attributed to the carbohydrate-recognition domain, a
common feature of other C-type lectins. In contrast, we ﬁnd that the features of MBL binding to Aβ are more similar to the
reported binding characteristics of the cysteine-rich domain of the unrelated mannose receptor and therefore may involve the
MBL cysteine-rich domain. Diﬀerences in MBL ligand binding may contribute to modulation of inﬂammatory response and may
correlate with the function of MBL in processes such as coagulation and tissue homeostasis.
1.Introduction
The innate immune system provides the ﬁrst line of host
defense, and in healthy individuals this defense is constitu-
tively present and active. Successful innate immune protec-
tion is achieved through two steps: ﬁrst, identifying targets,
suchaspathogensand abnormalself-tissueand cells;second,
orchestrating humoral and cellular eﬀectors to eliminate the
identiﬁed targets and induce appropriate host responses,
including appropriate inﬂammation and resolution. Cellular
elements of the innate immune system include phagocytes,
macrophages, epithelial cells, and endothelial cells. Humoral
components include pattern recognition molecules, comple-
ment proteins, coagulation proteins, and cytokines. More-
over, in addition to immune functions, the innate immune
system includes coagulation and inﬂammation functions
that are essential to the maintenance of tissue homeostasis
[1, 2].
Activation of the innate immune system can be initiated
bypatternrecognitionmolecules,whicharepresentonavar-
iety of innate immune cells, bound within the extracellular
matrix, and circulating as soluble molecules in blood. One
such soluble pattern recognition molecule is mannose-bind-
ing lectin (MBL), which is primarily (>95%) synthesized in
the liver and secreted to circulate in the blood [3–6]. Al-
though MBL protein has also been found in other organs,
suchasskin,brain,andlung,itsmRNAhasnotbeendetected
in those areas [3, 4, 7–10], suggesting that MBL may be re-
cruited to regions where its targets are located. MBL modu-
lates inﬂammation in infection and tissue injury [2, 11, 12],2 Journal of Biomedicine and Biotechnology
with extensive interactivity with inﬂammatory and other
complement pathways [13, 14]. Concerted action of these
systems is required to maintain homeostasis, as dysfunction
may result in impaired immunity, autoimmunity, or other
disorder of homeostasis.
Genetic variation resulting in MBL deﬁciency is a com-
mon primary immunodeﬁciency [15–22]. There are three
single-nucleotide polymorphisms (SNPs) in the MBL gene,
located in the coding region of the collagen-like domain and
in the promoter region. Heterozygosity in these SNP loci
accounts for the majority of MBL deﬁciency, resulting in a
wide range of MBL blood concentrations, from undetectable
to as high as 10μg/mL [19, 20]. Additionally, MBL blood
levels vary with age and have been found to decrease signi-
ﬁcantly beyond the age of 40 [23]. MBL deﬁciency increases
susceptibility to certain pathogens, as we have reviewed pre-
viously and as revealed in subsequent animal infection stud-
ies on pathogens, including inﬂuenza A virus (IAV) and
Staphylococcus aureus (SA) [7, 11, 12, 24–30]. Animal studies
have also provided in vivo evidence that MBL modulates
inﬂammation [2, 7, 11, 12].
MBL functions as an opsonin and activates the lectin
complement pathway through association with MBL-asso-
ciated serine proteases (MASPs) [1, 3, 7, 31, 32]. In humans,
there are three proteolytically active MASPs: MASP-1,
MASP-2, and MASP-3. MASPs form complexes with MBL
[33, 34], and MBL binding to speciﬁc ligands is thought to
induce conformational changes that enhance the proteolytic
activity of the associated MASP. Recent results, including our
own, provide evidence that MBL and MASP 1–3 complexes
also mediate coagulation [1, 31, 35–37]p a t h w a y s .
Structurally, MBL comprises a cysteine-rich domain at
the N-terminus followed by a collagen-like domain, a neck
region and a carbohydrate recognition domain (CRD) at the
C-terminus [24]. Three single-MBL peptides of 35kD asso-
ciatetoformafunctionaltrimericsubunitthatfurthermulti-
merizes to formhigher-order oligomers, as large as hexamers
of trimers [24]. MBL recognizes many pathogens, including
b a c t e r i aa n dv i r u s e s ,a sw e l la sa b n o r m a ls e l ft i s s u e st h a t
contain endogenous neoepitopes that are exposed on apop-
totic cells, cell debris, and injured and damaged tissues
[3, 24, 38, 39]. These MBL targets contain chemical pat-
terns, including D-mannose, L-fucose, and N-acetyl-D-glu-
cosamine[3,24,38–42].Todate,investigationofMBLligand
binding has been focused on various carbohydrates and has
been principally attributed to the CRD. As the MBL CRD
requires calcium to bind many ligands, it is regarded as a
member of the C-type lectin family.
Another C-type lectin, mannose receptor (MR), is a
membrane receptor that yields a soluble form of its extracel-
lular domain as a cleavage product [43]. MR has 8 CRDs at
itsC-terminus,precededbyatypeIIﬁbronectin-likedomain
and a cysteine-rich domain (CysD) at its N-terminus [44].
CysD has been found to bind to sulfated carbohydrate resid-
ues of luteinizing hormone and blood type-determining
Lewis saccharides [45]. Such CysD-mediated MR target
binding is calcium independent [46, 47], in contrast to cal-
cium requirement for ligand binding within the CRD. There
are three cysteine residues in an 18 amino acid stretch within
the CysD of MBL, and 5 cysteines within an 84 amino acid
stretch within the CysD of MR [47, 48]. Although there is
otherwise little amino acid homology within the CysDs of
MBL and MR, it is possible that these CysDs share similar
physiochemical properties that enable binding to sulfated
carbohydrates.
Sulfated polysaccharides are abundant throughout the
body. Extracellular tissue matrices throughout the body are
rich in glycosaminoglycans, which are sulfated polysaccha-
rides [49] and sulfated proteoglycans.
We have previously identiﬁed important roles for MBL
and innate immunity in maintenance of tissue homeostasis
[1, 2]. We have considered whether these homeostatic mech-
anismsmayrelatetothebrain,andspeciﬁcallywehavetested
the interaction of MBL with amyloid β (Aβ). Aβ has been
associated with Alzheimer’s disease (AD) [50, 51], and it has
b e e no b s e r v e dt h a ta b n o r m a la c c u m u l a t i o ni nA Di sp r i n -
cipally related to decreased clearance [52]. Consequently, we
have developed the hypothesis that MBL plays a role in brain
homeostasis that may include Aβ clearance.
We present data demonstrating that MBL, a pattern
recognition of the innate immune system, recognizes speciﬁc
chemical epitopes of bacterial and viral pathogens, repre-
sented here by Staphylococcus aureus and inﬂuenza A virus,
aswellasanendogenous epitope, representedbytheamyloid
β molecule. This versatility demonstrates the central role of
the innate immune system in providing immune protection
from pathogens as well as maintaining homeostasis of self-
tissues. We also present investigations of the inﬂammatory
responsesrelatedtothesemoleculesinaninvitrosystemand
discuss the potential implications of our ﬁndings.
2.MaterialsandMethods
2.1. Reagents. L-Fucose, sodium fucoidan (from Fucus vesi-
culosus, MW 170kD), and sodium heparin (porcine, unfrac-
tionated) were purchased from Sigma-Aldrich. L-Fucose
sulfate was synthesized according to the methods described
by Forrester [53], yielding a mixture of monosubstituted L-
fucose sulfates at diﬀerent carbon centers. Figure 1 shows
chemical structures of these sugars as well as mannan, the
best characterized MBL ligand. Amyloid β (Aβ)p e p t i d e s ,
both Aβ40 and Aβ42, were purchased from rPeptide and re-
suspended at 1mg/mL according to the manufacturer’s
i n s t r u c t i o n .A l i q u o t sw e r es t o r e da t−80◦C and sonicated
(Branson, duty cycle 60 and output setting 6, resulting in
30% output) prior to use.
Inﬂuenza A virus (IAV); strain A, Puerto Rico, 34 (re-
ferred to as PR8) was prepared as previously described [54].
Brieﬂy, IAV was grown in the chorioallantoic ﬂuid of chicken
eggs and puriﬁed on a discontinuous sucrose gradient (Sig-
ma-Aldrich). Virus stocks were dialyzed against PBS (Sigma-
Aldrich), and aliquots were stored in a −150◦Cf r e e z e r .V i r u s
was sonicated prior to use, as for Aβ. Hemagglutinin (HA)
titers were determined by titration with human blood type
O, Rh− red blood cells (RBCs) in PBS.Journal of Biomedicine and Biotechnology 3
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Figure 1: Chemical structures of polysaccharides used in this study, with the mannan structure for comparison. Representative repeating
units are shown for mannan, heparin, and fucoidan. The average molecular weight of the fucoidan preparation used for this work is ap-
proximately 170kD. The porcine heparin used in these experiments is unfractionated, with a range of diﬀerent molecular weight species.
L-fucose-2-sulfate is depicted here.4 Journal of Biomedicine and Biotechnology
S. aureus (SA) was grown in Columbia broth with 2%
NaCl to a mid-log phase and washed with saline. Aliquots
(5 × 108 colony forming units (cfu)/mL) were stored at
−20◦C.
Recombinant human MBL (MBL) was a gift from Enzon
Pharmaceuticals Inc.
2.2.MBLBindingAssay. These assays were performed as pre-
viously described, with minor modiﬁcations [11]. Initially,
Aβ peptides were tested using concentrations of 0.05, 5, 500,
and 50,000ng/mL to measure the dose response of MBL
binding. Subsequently, Aβ peptides were used at 50,000ng/
mL for all other studies. Assays were carried out in 384 well
polystyrene plates with 20μL total volume per well. Wells
were coated with Aβ40, Aβ42, IAV (strain PR8, 1000−1 he-
magglutinin titer/mL), or S. aureus (Reynolds, 5 × 105 cfu)
in 20μL of 0.2M carbonate buﬀer, pH 9.5, and incubated
12h at 4◦C. After rinsing with 10mM Tris, pH 7.4, 120mM
NaCl (TBS) with 10mM CaCl2 and 0.5% Tween 20 (washing
buﬀer), plates were blocked with 0.1% BSA in TBS-Ca buﬀer
for 1hr at room temperature with gentle agitation. Test sam-
plesweredilutedinTBS-Cabuﬀerto2μg/mLofMBL.Excess
liquid was shaken oﬀ and test samples (20μL/well) were
added and incubated as above. Where indicated, carbo-
hydrate inhibitors were added. After rinsing, bound MBL
was detected by incubating with anti-MBL antibody (2A9)
[55], followed by alkaline phosphatase-conjugated goat anti-
mouse IgG (1:7500, Promega) and pNPP substrate solution
(Sigma-Aldrich). Reactions were read at OD 415nm using
a Spectramax plate reader (Molecular Devices). Results are
expressed as OD 415nm reading as well as % of MBL alone.
For carbohydrate inhibition studies, carbohydrate com-
pounds were used at 5mg/mL, which is within the usual
rangeusedforMBLbindinginhibition.Forthemonosaccha-
rides, L-Fucose and L-fucose sulfate, this represents 27mM
and13mM,respectively,whichisintherangeofthereported
50% inhibitory concentrations of L-fucose for MBL [56]. In
tests of calcium dependency, 20mM EDTA was used.
2.3.MiceandMiceSera. MBLnullmicewer epr eviouslygen-
erated and fully backcrossed onto C57Black/6J [2, 11]. Sera
were collected by cardiac puncture of euthanized mice and
serafromatleast5micewerepooledandaliquotswerestored
at −80◦C. All animal experiments were performed under
a protocol approved by the Subcommittee on Research Ani-
mal Care at Massachusetts General Hospital, Boston, MA,
USA.
2.4. Cytokine Assay. Peritoneal macrophages (MΦ)o fw i l d
type C57Black/6J (Jackson Laboratories) were prepared by
peritoneal lavage performed 4-5 days after intraperitoneal
injection of 2mL of 3% thioglycolate (DIFCO). Assays were
performed using 96 well plates. MΦsw e r ep l a t e da t1×
105 per well in 50μL RPMI culture medium containing 10%
s e r u mo fw i l dt y p eo rM B Ln u l lm i c ea n dc u l t u r e da tl e a s t
1hrina5%CO 2 incubator at 37◦Ct oa l l o wM Φsa d h e r et o
the plate. Aβ40 (1μg), Aβ42 (1μg), IAV (strain PR8, 1000−1
hemagglutinin titer), or S. aureus (Reynolds, 1 × 106 cfu)
was prepared in 10% serum of wild type or MLB null mice.
To test the inhibitory eﬀects of a sulfated polysaccharide,
heparin was added to a ﬁnal concentration of 0, 0.1, 1, or
10μg/mL in a total volume of 100μL per well. Plates were
cultured for 2hrs at 37◦Ci na5 %C O 2 incubator. 70μLo f
culture supernatant was collected into U bottom plates and
stored at −80◦C for subsequent measurement of cytokines.
Assays were performed in duplicate.
IL-6 and TNF-α were assayed using ELISA kits (DuoSet,
R&D systems) according to the manufacturer’s instruction.
Supernatant was diluted to 1:10 and 1:1 for the IL-6 and
TNF-α assays, respectively. Results are expressed as pg/mL of
IL-6 and TNF-α.
2.5. Statistical Analysis. All data was analyzed by Student’s
t-test using JMP software (SAS Institute Inc.). P values less
than 0.05 are considered to be signiﬁcant.
3. Results
3.1. MBL Binds to Aβ Peptides. There is dose-dependent
binding of MBL to Aβ peptides, within increased binding of
MBL in the presence of increased amounts of Aβ (Figure 2).
Under the reaction conditions tested here, there was similar
binding of MBL to Aβ40 (Figure 2(a))a n dA β42 (Figure
2(b)), and similar dose dependence. We next evaluated the
speciﬁcity of the MBL binding to Aβ using multiple inhi-
bitors.
3.2. MBL Ligand Binding Is Inhibited by Polysaccharides, and
More Strongly Inhibited by Sulfated Polysaccharides. Based
upon the observation that sulfated polysaccharides are rec-
ognized bythe CysDof MR [46],we investigated MBLligand
binding in the presence of diﬀerent nonsulfated and sulfated
carbohydrates. MBL binding to Aβ peptides was compared
with MBL binding to IAV and SA. L-Fucose, a well-known
inhibitor of MBL binding, did not signiﬁcantly inhibit MBL
binding to Aβ, although it did signiﬁcantly inhibit MBL
binding to IAV and SA, as expected (Figure 3). In contrast,
sulfated carbohydrates such as L-fucose sulfate, fucoidan,
and heparin showed signiﬁcant inhibition of MBL binding
toalltargets.Theinhibitioncausedbysulfatedcarbohydrates
was signiﬁcantly greater with MBL binding to Aβ compared
with MBL binding to virus and bacteria and was most pro-
nounced with heparin. These results demonstrate that there
is speciﬁcity of MBL binding to the tested ligands, as this
binding is inhibited by speciﬁc carbohydrates. However,
there is a diﬀerence between MBL binding to Aβ,w h i c hi s
not signiﬁcantly inhibited by L-fucose (a known competitive
inhibitor of binding to the MBL CRD) and MBL binding to
IAVandSA.Additionally,whereassulfatedcarbohydrates(L-
fucose sulfate, fucoidan, and heparin) strongly inhibit MBL
binding to Aβ, they are relatively weak inhibitors of MBL
binding to IAV and SA.
3.3. Calcium Dependency of MBL Ligand Binding. We tested
the calcium dependence of the most eﬀective inhibitors
identiﬁed in the previous experiment, fucoidan and heparin,Journal of Biomedicine and Biotechnology 5
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Figure 2: Dose response of MBL binding to Aβ40 (a) and Aβ42 (b) peptides. MBL binding to Aβ was measured with Aβ peptide concen-
trations of 0.05, 5, 500, and 50,000ng/mL (Figure 2). Assays were performed in triplicate, as described in Section 2. Data are expressed as
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both of which are sulfated polysaccharides. CRD-mediated
ligand binding is calcium dependent, whereas CysD-med-
iated ligand binding is not. EDTA inhibits MBL-binding to
all tested ligands (Figure 4), which is consistent with the
hypothesis that the MBL CRD is involved with binding to
each them. Similarly, the sulfated carbohydrates fucoidan
and heparin both inhibit MBL binding to all tested ligands.
Surprisingly, however, EDTA together with sulfated carbo-
hydrate showed decreased inhibition of MBL binding to Aβ.
This contrasts with the increased inhibition of MBL binding
to both IAV and SA with the combination of heparin and
EDTA. The apparent relief of inhibition of MBL binding to
Aβ caused by EDTA suggests that impairing binding through
the CRD, by removing Ca2+, potentiates MBL binding to Aβ,
perhaps through a domain other than the MBL CRD.
3.4. MBL Modulates Inﬂammatory Responses of Macrophages.
ProductionofIL-6andTNF-αfromWTmacrophagesinres-
ponse to Aβ peptides, IAV or SA was examined with serum
from wild type or MBL null mice. IL-6 production was sig-
niﬁcantly higher in MBL null serum compared to WT serum
(Figure 5(a)). Moreover, IL-6 production was signiﬁcantly
higher in the presence of SA compared to all other ligands
(Figure 5(a)).
In contrast, TNF-α production was slightly higher in WT
serum, although this was not statistically signiﬁcant (Figure
5(b)). In both MBL null and WT sera, SA, and Aβ42 peptide
provoked signiﬁcantly higher TNF-α production compared
with medium alone (Figure 5(b)). In contrast, Aβ40 peptide
had no signiﬁcant eﬀect on TNF-α production. IAV pro-
voked trace TNF-α production in MBL null serum, and
showed no signiﬁcant diﬀerence compared with media alone
in WT serum.
3.5.TNF-αandIL-6ProductionIsM odulatedbyH eparin. We
next examined the eﬀect of heparin, an endogenous sulfated
polysaccharide, on inﬂammatory responses of peritoneal
macrophages. IL-6 production in both MBL null and WT
sera was signiﬁcantly inhibited by 10μg/mL of heparin with
all ligands: SA, IAV, and Aβ peptides (Figures 6(a)–6(d)).
Heparin’s inhibitory eﬀect was also observed at 1μg/mL for
IAV and Aβ40 peptide (Figures 6(b) and 6(c)).
TNF-α production in WT serum was signiﬁcantly inhib-
ited by 10μg/mL of heparin with all ligands: SA, IAV, and Aβ
peptides(Figures6(e)–6(h)).ForbothAβ40andAβ42,inhi-
bition was also observed in MBL null serum (Figures 6(g)
and 6(h)). In contrast, heparin signiﬁcantly increased TNF-α
production in MBL null serum with SA, while there was no
TNF-a production in MBL null serum with IAV, as before
(Figures 6(e) and 6(f)).
4. Discussion
Our data demonstrate that MBL binds to IAV, SA, and Aβ
peptides. We have previously reported MBL binding to IAV
and SA; however, binding to Aβ peptide is reported here for
the ﬁrst time. MBL recognition of Aβ is demonstrated to be
speciﬁc, as it is disrupted by speciﬁc inhibitors. Carbohy-
drates, and especially sulfated polysaccharides, inhibit MBL
binding to Aβ as well as to SA and IAV ligands. The eﬀects
of EDTA, which removes Ca2+ required by the MBL CRD for
ligand binding, vary depending on the ligand. Based on this
data,weputforwardthehypothesisthatinadditiontoligand
recognition through its CRD, MBL may bind certain ligands
through another moiety, and we suggest that the CysD is a
likely candidate for an alternative binding site.
Interestingly, MBL binding to Aβ peptides, unlike virus
and bacteria, was not inhibited by L-fucose, which is known
to bind in a calcium-dependent manner to the MBL CRD.
This ﬁnding is consistent with MBL binding to Aβ outside
the CRD. However, EDTA, which chelates and removes Ca2+
from the MBL CRD, does inhibit MBL-Aβ interaction, sug-
gesting that the carbohydrate recognition mechanisms of the
MBL CRD may be more complex. Mannan and GlcNAc,
which are widely used as speciﬁc inhibitors of MBL ligandJournal of Biomedicine and Biotechnology 7
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binding, do not inhibit MBL binding to Aβ interaction (data
not shown). Furthermore, EDTA diminishes the inhibitory
eﬀects of heparin and fucoidan on MBL binding to Aβ pep-
tides, and particularly Aβ40. Taken together, these results
suggest that the MBL CRD with a ligand other than Ca2+
bound may impair the ligand binding ability of the MBL
CysD.
Our results also show interaction of MBL and heparin,
which inhibits binding of MBL to Aβ,I A V ,a n dS A .T h i sa p -
pears to be a new ﬁnding, although our experiments are not
deﬁnitive. In our work demonstrating abnormality in bleed-
ing time in MBL null mice, we related this phenomenon to
MBL activation of a thrombin-like activity that contributes
to coagulation, and which when deﬁcient resulted in de-
creased coagulation [1]. The ﬁndings presented here suggest
that these systems may be more complex, with MBL binding
to endogenous anticoagulant glycosaminoglycans (such as
heparins) possibly contributing to thrombosis, and further
investigation is needed to understand the mechanisms and
signiﬁcance of this phenomenon.
Although we have not performed rigorous experiments
todeterminetheaﬃnityofMBLbindingtotheligandstested
here, there was signiﬁcantly greater MBL binding to IAV and
SA compared with Aβ peptides. It is diﬃcult to compare
these diﬀerent types of ligands, as the Aβ peptides are in an
undeﬁned state of aggregation, and the IAV and SA both
present a complex and heterogeneous surface. For example,
SA expresses lipoteichoic acid, wall teichoic acid, and cap-
sular polysaccharides, while IAV expresses hemagglutinin
that is heterogeneously glycosylated. It is also possible that
these pathogens may have multiple ligands that can be rec-
ognized by the MBL CRD and CysD independently, resulting
in increased MBL binding. We are currently undertaking
derivative studies to better characterize MBL binding to
diﬀerent ligands, including diﬀerent forms of Aβ.
We have previously reported that MBL is a proinﬂam-
matory molecule. For instance, production of inﬂammatory
cytokines, including IL-6 and TNF-α, was signiﬁcantly lower
in MBL null mice sera at an early time point (2 hours) fol-
lowing SA blood infection in vivo [11]. Other subsequent in
vitro studies provided concordant data that MBL facilitates
induction of TNF-α and IL-6 from macrophages [57]. Base-
line TNF-α levels are similar in MBL null and WT sera, and
overall TNF-α production in response to SA and Aβ peptide
is slightly higher (not statistically signiﬁcant) in WT serum
than MBL null serum. Although the eﬀects of TNF-α have
been considered in the brain, it is not clear that its eﬀects are
harmful or beneﬁcial [58]. Although TNF-α production by
macrophages in response to Aβ42 peptide has been reported,
theroleofMBLinthisprocesshasnotbeeninvestigated[59].
Interestingly, TNF-α production by peritoneal macro-
phages was undetectable in response to IAV in MBL null
serum,butnotinWTserum.MBLhasbeenshowntobindto
and even neutralize IAV [7, 60]. Therefore, it is possible that
inourexperimentalsystemMBLplayedaroleinmaking IAV
available to the macrophages, and these results support our
previous observations that MBL promotes TNF-α produc-
tion in response to stimuli. Similarly, Aβ peptides, in par-
ticular Aβ42, appear to stimulate TNF-α production from
macrophages, and this process is enhanced in MBL suﬃcient
WT serum compared to MBL null serum.
In contrast, IL-6 production is signiﬁcantly higher in
MBL null serum compared to WT serum in response to all
stimuli:IAV,SA,andAβ peptides.Theseresultscontrastwith
our previous paper, which also studied murine macrophages
but with 1% fetal bovine serum [61], and it is possible that
cytokine responses may diﬀer depending on the serum used
(unpublished observations). Although production of both
TNF-α and IL-6 is stimulated by NFκB pathways, our results
support the concept that there are additional factors related
to cytokine production [62, 63].8 Journal of Biomedicine and Biotechnology
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Figure 6: Eﬀects of heparin on cytokine responses to Aβ40, Aβ42, IAV, or SA. The assays were performed as in Figure 5. Heparin was used at
0, 0.1, 1, and 10μg/mL mixed with Aβ40, Aβ42, IAV, or SA. IL-6 and TNF-α in the culture supernatant were determined and are expressed
as pg/mL ± SEM. Compared to WT serum, ∗P<0.05; ∗∗P<0.005; ∗∗∗P<0.0001 against all others.
The inﬂammatory responses of peritoneal macrophages
in our system were signiﬁcantly inhibited by heparin, and
particularly IL-6 production in MBL null serum. A similar
inhibitory eﬀect was also observed for TNF-α, with the
exception of response to IAV and SA in the absence of MBL.
MBL null mice are susceptible to these pathogens, as we pre-
viously reported, and deranged inﬂammatory modulation
related to heparin in the absence of MBL may also contribute
to susceptibility to infection [7, 11]. We note that the greatest
inhibitory eﬀects in our system were observed at heparin
levels of 10μg/mL, corresponding to 1.76 units/mL. As tissue
heparin is reportedly on the order of 1–45 units/g, the levels
used here can be achieved locally in tissues [64].
The inhibitory eﬀects of heparin on inﬂammation re-
ported here support previous speculation that heparin may
reduce Aβ-mediated inﬂammation [65]. Likewise, this anti-
inﬂammatory activity may be related to the beneﬁcial eﬀects
of exogenous low-molecular-weight heparin in a mouse
model of amyloidopathy [66]. Heparin has also been shown
to modify amyloid precursor protein processing and Aβ ag-
gregation [67–69].
In conclusion, our investigations demonstrate that MBL
binds to a variety of ligands, including Aβ peptides, possibly
through both the CRD and CysD regions. Further, it is pos-
siblethatsomeligands,suchasAβ,maypreferentiallybindto
the CysD, as depicted in Figure 7.W eh a v ef o u n dt h a tM B LJournal of Biomedicine and Biotechnology 9
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Figure 7: A proposed model of MBL-ligand-binding modes. Figures on the right and left both represent tetramers of MBL trimers. On the
left, the MBL molecule is shown binding to pathogens by both the CRD and CysD regions. On the right, sulfated carbohydrates are depicted
binding to both the CRD and CysD regions, which may inhibit binding of ligands, including Aβ, to the CysD. Additionally, the CRDs may
have alternative bindings modes, which allow recognition of carbohydrate and noncarbohydrates, possibly including Aβ. Antibodies are
shown binding to the collagen domain of MBL, corresponding to the anti-MBL antibodies used in the ELISA experiments reported here.
binding to diﬀerent ligands results in modulation of the in-
ﬂammatory response with peritoneal macrophages. Addi-
tionally,MBLbindingtopathogensmayhavediﬀerenteﬀects
depending upon the ligand composition of the pathogen
surface [61, 70].
The possibility of diﬀerent ligand-binding modes for
MBL leads to the hypothesis that MBL plays diﬀerent roles
in diﬀerent host systems, such as immunity, coagulation, and
homeostasis. With respect to the latter, our ﬁnding that MBL
recognizes Aβ leads to consideration of the role of these dif-
ferent systems in the maintenance of brain homeostasis. Spe-
ciﬁcally, in recognition that Aβ clearance is insuﬃcient in
Alzheimer’s disease patients [52, 71], we propose that MBL
may play a role in Aβ clearance, which may be a normal ele-
ment of brain homeostasis.
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